AT-Patch (ATP-C130/ATP-C70) vs Reveal LINQ

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AT-Patch (ATP-C130/ATP-C70)

by ATsens Co.

Reveal LINQ

by Medtronic

AI Verdict

AT-Patch is a non-invasive, short-term (up to 14 days) wearable ECG monitor ideal for initial diagnostic screening or post-event monitoring. In contrast, Reveal LINQ is a minimally invasive, long-term (up to 3 years) implantable cardiac monitor designed for detecting infrequent arrhythmias, cryptogenic stroke, or unexplained syncope where extended monitoring is crucial. While both leverage AI for arrhythmia detection and remote monitoring, their differing deployment methods and monitoring durations cater to distinct clinical needs.

Choose AT-Patch (ATP-C130/ATP-C70) if…

Choose AT-Patch if you require a non-invasive, short-to-medium term ambulatory ECG monitoring solution, typically up to 14 days, for initial arrhythmia detection or post-treatment assessment. Its shower-proof design and lightweight nature make it suitable for patients needing continuous monitoring with minimal disruption to daily activities.

View AT-Patch (ATP-C130/ATP-C70) →

Choose Reveal LINQ if…

Choose Reveal LINQ if long-term, continuous cardiac monitoring (up to three years) is necessary to diagnose infrequent or elusive arrhythmias, such as those associated with cryptogenic stroke or unexplained syncope. This implantable device provides discreet, extended monitoring without patient interaction, ideal for comprehensive diagnostic periods.

View Reveal LINQ →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AT-Patch (ATP-C130/ATP-C70)	Reveal LINQ
Pricing	N/a	Contact vendor for pricing
Deployment	Wearable device for patients; analysis software deployed on-premise at medical institutions.	Implantable medical device with a bedside patient monitor (MyCareLink™) for data transmission and a mobile app (Reveal LINQ™ Mobile Manager) for clinicians.
FDA Status	1 AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AT-Patch (ATP-C130/ATP-C70)

AT-Patch is a non-invasive wearable device that patients can apply and manage themselves, offering a smartphone app for live ECG viewing and symptom recording. While Reveal LINQ is highly passive once implanted, it requires a medical procedure for insertion, making AT-Patch more broadly 'usable' from a patient's self-management and non-invasiveness perspective for shorter-term monitoring.

Clinical Value

Reveal LINQ

Reveal LINQ offers significantly longer continuous ECG monitoring (up to three years) compared to AT-Patch's 14 days, which is critical for detecting infrequent or elusive arrhythmias. Its AccuRhythmu2122 AI algorithms are specifically designed to reduce false alerts, enhancing diagnostic accuracy for conditions like atrial fibrillation, cryptogenic stroke, and unexplained syncope.

Pricing & Value

Tie

Neither tool provides public pricing, making a direct comparison on cost difficult. AT-Patch, as a wearable, likely has a lower per-use cost, offering value for shorter-term diagnostic needs. Reveal LINQ, an implantable device, likely involves higher upfront costs but provides long-term, continuous monitoring value for complex cases where extended surveillance is necessary. Without specific pricing, it's challenging to determine a clear winner on overall value.

Enterprise Readiness

Reveal LINQ

Medtronic, as a large and established medical device company, likely provides robust enterprise support, established integration pathways (CareLink network), and explicit statements regarding HIPAA compliance and patient data protection for Reveal LINQ. AT-Patch's on-premise software deployment might offer control but could present different integration challenges compared to Medtronic's extensive infrastructure.

Innovation

Reveal LINQ

Reveal LINQ stands out for its miniaturization as the 'world's smallest insertable cardiac monitor' and its capability for continuous monitoring for up to three years. Its AccuRhythmu2122 AI algorithms specifically target reducing false alerts, which is a significant innovation addressing a key clinical challenge in long-term monitoring.

Support & Docs

Reveal LINQ

While specific details are not provided for either tool in the facts, Medtronic, as a global leader in medical technology, is known for its comprehensive support, training, and extensive documentation for its complex medical devices like Reveal LINQ. ATsens Co., being a smaller company, is unlikely to match the scale and breadth of Medtronic's established support infrastructure.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AT-Patch (ATP-C130/ATP-C70)	Reveal LINQ
Name	AT-Patch (ATP-C130/ATP-C70)	Reveal LINQ
Company	ATsens Co.	Medtronic
Continuous Monitoring Duration	Up to 14 days (ATP-C130)	Up to three years
AI/Machine Learning	AT-Report software with AI/machine learning algorithms for ECG analysis	AccuRhythmu2122 AI algorithms for reduced false alerts (AF and pause)

Videos

Demos, reviews, and walkthroughs featuring AT-Patch (ATP-C130/ATP-C70) and Reveal LINQ.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary differences in monitoring duration and device type between AT-Patch and Reveal LINQ?

The AT-Patch is a wearable ECG monitor offering up to 14 days of continuous cardiac monitoring. In contrast, the Reveal LINQ is a tiny, implantable cardiac monitor that continuously records ECG for up to three years.

How do these devices differ in terms of patient experience and convenience?

The AT-Patch is a compact and lightweight (13g) wearable with a shower-proof design, requiring no charging or electrode replacement during its monitoring period. The Reveal LINQ is an implantable device that offers long-term, continuous monitoring for up to three years with a minimally invasive insertion procedure.

What are the capabilities of the AI algorithms in each device for arrhythmia detection?

AT-Patch utilizes AT-Report software with AI/machine learning algorithms for ECG analysis and enhanced arrhythmia detection. Reveal LINQ features AccuRhythmu2122 AI algorithms designed to accurately detect and diagnose cardiac arrhythmias, including atrial fibrillation and pause, while aiming to significantly reduce false alerts.

How is data transmitted and accessed by clinicians for each device?

For AT-Patch, patients can use the AT-Note smartphone app for live ECG viewing and symptom recording, with analysis software deployed on-premise at medical institutions. Reveal LINQ wirelessly transmits data to the CareLinku2122 network via a MyCareLinku2122 Patient Monitor, and clinicians can manage the device using the Reveal LINQu2122 Mobile Manager app.

Is either device compatible with MRI procedures?

The Medtronic Reveal LINQ is MRI Conditional for both 1.5T and 3T, with no post-insertion waiting period required. The AT-Patch's provided information does not explicitly mention MRI compatibility.

What are the typical use cases or patient populations best suited for each device?

The AT-Patch is suitable for short-term continuous cardiac monitoring, up to 14 days, for general arrhythmia detection in ambulatory patients. The Reveal LINQ is indicated for long-term monitoring, up to three years, for patients experiencing transient symptoms such as dizziness, palpitations, syncope, and chest pain, or those at increased risk of cardiac arrhythmias, including atrial fibrillation and cryptogenic stroke.